Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KOD
Strong SellSinkerKodiak Sciences Inc. · Healthcare · United States · $2.4B · Avg Vol: $20M/d
COMPANY DESCRIPTION
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for common retinal diseases, such as wet AMD and diabetic macular edema. The company's competitive edge lies in its proprietary KSI technology platform, which aims to create long-acting intravitreal treatments to reduce patient injection burden. It operates as a focused biotech player, leveraging its specialized platform to address significant unmet medical needs in ophthalmology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 34.4M | — |
| EPS | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 | — | -4.19 | -3.99 | -3.75 | — |
| Shares | 51.8M | 52.3M | 52.5M | 52.7M | 61.8M | +19.2% | 62.8M | — | — | — |
| Debt | 80.0M | 87.7M | 81.6M | 70.3M | 59.2M | -7.3% | 52.8M | — | — | — |
| Equity | 663.3M | 436.2M | 265.8M | 150.3M | 157.4M | -30.2% | — | — | — | — |
| Op CF | -182.3M | -206.5M | -154.2M | -117.3M | -136.0M | — | -158.5M | — | — | — |
| Inv CF | -38.8M | -336.5M | 249.2M | -0.8M | -0.5M | — | — | — | — | — |
| Fin CF | 8.2M | 1.9M | 31.0K | 0.5M | 178.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KOD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc.(you) | $2.4B | 12 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.5B | 8 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| BHVN | Biohaven Ltd. | $2.3B | 18 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%